SCHEMBL23045341

SCHEMBL23045341

CN(C)Cc1ccc(Nc2nc3ccc(Cl)cc3c(=O)n2-c2ccccc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 1/20 0.48
KDM1A O60341 1/20 0.42
BPTF Q12830 1/20 0.42
MAT2A P31153 3/20 0.42
NPC1 O15118 1/20 0.41
JUN P05412 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
PRMT5 O14744 1/20 0.40
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40
TUBA1B P68363 1/20 0.40
TUBA4A P68366 1/20 0.40
TUBB4B P68371 1/20 0.40
TUBB3 Q13509 1/20 0.40
TUBB2A Q13885 1/20 0.40
TUBB8 Q3ZCM7 1/20 0.40
TUBA3E Q6PEY2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29623309 1.00 ACP1 (0.48) ACP1KDM1ABPTFMAT2ANPC1
SCHEMBL23065069 0.91 MAT2A (0.45) ACP1KDM1AMAT2APRMT5
SCHEMBL29746906 0.91 MAT2A (0.45) ACP1KDM1AMAT2APRMT5
SCHEMBL24090131 0.91 MAT2A (0.44) ACP1BPTFMAT2APRMT5
SCHEMBL24089920 0.90 PRMT5 (0.41) MAT2ANPC1JUNNFKB1NFKB2
SCHEMBL29623221 0.90 PRMT5 (0.41) MAT2ANPC1JUNNFKB1NFKB2
SCHEMBL24090011 0.90 ACP1 (0.50) ACP1MAT2A
SCHEMBL24089969 0.89 IDO1 (0.42) ACP1BPTF
SCHEMBL24090006 0.88 TDO2 (0.51) ACP1
SCHEMBL23045330 0.87 KDM4E (0.44) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114650986-A 2-aminoquinazolinone derivatives 住友制药株式会社 2022-06-21 CN disclosed
US-11352366-B2 2-aminoquinazolinone derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-06-07 US disclosed
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-05-12 US disclosed
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-09 US disclosed
WO-2021039968-A1 2-AMINOQUINAZOLINONE DERIVATIVE 大日本住友製薬株式会社 2021-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, CRKL ACP1 3959/4885KDM1A 1398/4885BPTF 4330/4885
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, SLC26A3 ACP1 4435/4885KDM1A 1575/4885BPTF 4383/4885
US-11352366-B2 2-aminoquinazolinone derivative CNKSR1, HAX1, SLC26A3 ACP1 4435/4885KDM1A 1575/4885BPTF 4383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.